

ANIMAL CARE AND USE PROTOCOL

For Teaching

Mahidol University-Institute Animal Care and Use Committee (MU-IACUC)

- 2 Overview
- This section will be completed by the MU-IACUC

Protocol number	F05 -
Date of submission (dd/mm/yy)	
Date of Request modification (dd/mm/yy)	
Date of Resubmitted (dd/mm/yy)	
Date of Approved/Disapproved (dd/mm/yy)	
Date of Expiration (dd/mm/yy)	

4	1. Subject:
5	(Thai)
6	(English)
7	Course Course Title
8	Study level
9	(*Please attach course syllabus)
10	2. Course coordinator: The names of each person, under this section, will be appeared on
11	the "Certificate of Approval".
12	Name
13	Position:Department
14	Faculty/Institute
15	TelE-mail
16	* Animal use license noExpired date
17	*Issued by Institute of Animal for Scientific Purposes Development, NRCT
18	3. Contact person in case of emergency:
19	Name
20	Position:Department
21	Faculty/Institute
22	Work phoneMobile phone
23	F-mail

24	6. Duration of Protocol:		
	Period for which the protocol is required	Years	Months
	(must not exceed three years)		
	Start date	End date	
	Please submit your application one to two	months (prefe	rably two months) before your
	planned start date.		
25	(The start date has to be after the date of a	pplication subi	mission. Please note that no
26	animal use may occur until the Animal Ethic	cs Committee a	approves, and all animal use mus
27	be finished before the end date. The date for	ormat is dd/mr	m/yyyy.)
28	*Animal care and use protocol for teaching	g certification p	period is up to 3 years depend or
29	decision of MU-IACUC]		
31 32 33 34	information herein is true and correct and standard of animal care and use establish the Mahidol University and Office of the Nathe Animal for Scientific Purpose Act., B.E. 2	ned under the ntional Researc	ethical guidelines and policies o
35	Course coordinator:		Date
36	()
37	The signature of Dean of Faculty /	Head of Insti	tute verifies that he / she
38	acknowledges the fact that P.I. under t	this affiliation	will conduct the animal care
39	and use protoco	l, as provided	herein.
40	Head of Faculty/Institute:		Date
41	()
40	Eaculty/Inctitute		

	MAHIDOL UNIVERSITTY
	RESEARCH PROTOCOL FORMAT
	FOR PERMISSION OF ANIMAL CARE AND USE
Type of animal pro	otocol
☐ Full Protocol	Exemption Protocol (answer only item 1-4, 6-8, 9.1.1and 22-24)
-	on : (Provide a brief, only one A4 page, and simplified description of the value of understood by non-scientists, expressing its significance and needs for dy).
information being	terature review: (Include a brief statement of the requirement for the g sought. Typically, the literature or the experience that led to the briefly reviewed, references cited will be provided).
3. Reference search details).	h: (Please specify the references used for researching the course
4. Objective(s): (Pro	ovide goal/specific aim of this project)
	ts of the study: Explain how the study is important to human or animorancement of knowledge

-	ing the animals to th	-	•	ment(s). [Diagran	n(s) or
	company complex ex	_				
7.0.	l de de de l ad	. 1 0 4				
	and statistical met		tatistica	l metnoa	s to c	e usec
, -	ults and for testing th	.,				
	d Source of samples	-				
	scription of animals i			Ι		
Common name	species	Strain/ Stock	Age	Weight	Sex	Numl
8.2 Students /	animal					
8.3 Permanent	animal ID method: (eg. ear tag, ear p	unch, m	nicrochip,	tattoo,	N/A,
other please sp	ecify)					
8.4 Special con	sideration: (List spec	ialized requireme	nts for t	the resear	ch anii	mals, if
any)						
	ndor:					
8.5 Source/Ver				onse sneci	fy):	
8.5 Source/Ver	sly approved protocol	. Protocol num	nber (ple	Jase specy		
8.5 Source/Ver	sly approved protocol ai) <i>please specify</i> :	•				
8.5 Source/Ver From previous Protocol Title (Th						
8.5 Source/Ver From previous Protocol Title (Th	ai) please specify:					
8.5 Source/Ver From previous Protocol Title (The Protocol Title (En Nature)	ai) please specify:					
8.5 Source/Ver From previous Protocol Title (The Protocol Title (En Nature) (If From wildlife in Protocol Title (In Protocol	ai) please specify: glish) please specify: .	n the Wildlife Pres	servatio	n and Pro	tectior	n Act
8.5 Source/Ver From previous Protocol Title (The Protocol Title (En Nature (If From wildlife in B.E.2562(2019) and	ai) please specify:glish) please specify: glish) please specify: nust be complied with ad National Parks Act	n the Wildlife Pres B.E.2562(2019), Pl	servatio	n and Pro	tectior permi	Act
8.5 Source/Ver From previous Protocol Title (The Protocol Title (En Installation Nature (If From wildlife in B.E.2562(2019) and document) please	ai) please specify: glish) please specify: . nust be complied with	n the Wildlife Pres B.E.2562(2019), Pl	servatio	n and Pro	tectior	Act ssion
8.5 Source/Ver From previous Protocol Title (The Protocol Title (En Installation Nature (If From wildlife in B.E.2562(2019) and document) please	ai) please specify:glish) please specify:nust be complied with and National Parks Act se specify:	n the Wildlife Pres B.E.2562(2019), Pl	servatio	n and Pro	tectior permi	n Act ssion
8.5 Source/Ver From previous Protocol Title (The Protocol Title (En Nature) (If From wildlife in B.E.2562(2019) and document) please Laboratory as	ai) please specify:glish) please specify:nust be complied with and National Parks Act se specify:	n the Wildlife Pres B.E.2562(2019), Pl please specify:	servatio	n and Pro	tectior permi	n Act ssion

	8.6 Explain why the proposed animal species is/are the most appropriate
	8.7 Provide a statistical analysis for estimation of sample size with an explanation for the number of animals to be used
	8.8 Transportation (if any, please specify how will the animals be transferred to the
	lab)
	8.9 Prevention of injury and/or infection
	8.10 Is the quarantine required?
	☐ Yes, specify the method, location and duration
9.	Animal care:
	9.1 Husbandry consideration: (Briefly describe animal housing and living conditions,
	routine animal observations, feed and water provisions, etc.)
	9.1.1 Study location (specify room number, name of building or facility)
	9.1.2 Housing system:
	☐ Clean conventional ☐ Strict hygienic conventional
	☐ Isolator maintained ☐ Barrier maintained
	☐ Laminar flow
	Other, please specify
	9.1.3 Caging:
	☐ Solid bottom, open top ☐ Static filtered top cages
	Suspended cages, wire bottom Metabolic cages
	Individual ventilated cage (IVC)
	lacksquare Other, please specify
	9.1.4 Cage size: W x L x H, (inch)
	9.1.5 Caging materials:
	Plastic Stainless steel
	Other, please specify
	9.1.6 Number of animals per cage:

131	9.1.7 Social housing (more than one animal per cage):			
132	(The IACUC requires social housing of all social animals)			
133	☐ Yes ☐ No			
134	If NO, provide scientific justification for not socially housing the animals. Describe			
135	what will be done to replace this social contact with conspecifics.			
136				
137	9.1.8 Environmental requirements:			
138	Temperature:			
139	Humidity:			
140	Light:			
141	Light cycle:			
142	9.1.9 Food			
143	Type of food:			
144	Feeding schedule: \square Routine feeding (ad libitum), \square Other, specify			
145	9.1.10 Water			
146	Type of water: \square Reverse osmosis, \square Other, specify			
147	Provision of water: \square Routine feeding (ad libitum), \square Other, specify			
148	9.1.11 Bedding			
149	□ No			
150	☐ Yes, please specify ☐ Sterile ☐ Non-sterile			
151	Type of bedding: \square Wood shaving \square Sawdust			
152	☐ Paper ☐ Other, specify			
153	Schedule of changing: \square Once a week, \square Other, specify			
154	9.1.12 Environmental Enrichment:			
155	☐ Accept			
156	Decline, provide scientific justification			
157				
158	9.2 Is this project intended to conduct the animal experiment in other building?			
159	(This is allowed for conducting experiment(s) only not for housing. In addition, the			
160	holding period must be less than 12 hours).			
161	□ No □ Yes, answer all that apply in 9.2.1 to 9.2.4			
162	9.2.1 Where the experiment is expected to be conducted? Please indicate the			
163	building name and room number.			
164				
165	9.2.2 Please provide the animal experimental procedures in detail.			
166				
167	9.2.3 Estimated total time period that live animals will be kept in the laboratory ishours			

	9.2.4 How will the animal sample or carcass be disposed?
	Veterinary medical care: (Describe the routine veterinary care. List the criteria used for alth evaluation while the animals are on study).
11.	Animal welfare:
	11.1 Replacement, Reduction and Refinement. (Briefly describe how you have
	considered each of the following alternatives (the 3Rs) or why they are not applicable).
	11.1.1 Replacement of animals (e.g., with in vitro models, computer models or less
	sentient animals)
	11.1.2 <u>Reduction in the number of animals</u> (e.g., using appropriate statistical
	methods in the design and analysis of the study; reduction in experimental
	variability by using animals of defined genetic or microbiological status)
	11.1.3 <u>Refinement of experimental procedures to minimize pain or distress</u> (e.g.,
	early endpoints; use of analgesics, anesthetics or sedatives; techniques that reduce
	stress in the animal.)
	11.2 Potential animal pain and distress assessment:
	11.2.1 Please indicate pain category according to USDA Pain and Distress. (Appendix A)
	☐ Category B: Animals being bred or housed without any research manipulations
	or non-invasive observation of animals in the natural habitat
	Number of animals
	☐ Category C: Animal use activities that involve no more than momentary or slight
	pain or distress (no greater than an injection) where there is no need for use oj
	pain-relieving drugs
	Number of animals
	☐ Category D: Animal use activities that involve accompanying pain or distress to
	the animals and for which appropriate anesthetics, analgesics, tranquilizing drugs
	and/or humane endpoints are used to avoid pain, distress, or discomfort
	Number of animals
	☐ Category E: Animal use activities that involve accompanying pain or distress to
	the animals and for which appropriate anesthetic, analgesic, tranquilizing drugs;

206	or other methods for relieving pain or distress are NOT used
207	Number of animals
208	Provide strong scientific justification as to why pain-relieving drugs or other methods
209	for relieving pain cannot be used on animals.
210	
211	
212	11.2.2 During the study:
213	1) How often will the clinical condition of animals be monitored?
214	
215	2) Who will monitor the clinical condition of the animals?
216	
217	11.2.3 Are the animals expected to experience any specific study-induced or
218	related problems (i.e. health problems, pain, distress, complications, etc.) or any
219	health problems as a result of the phenotype of the animal?
220	□ No □ Yes, answer all that apply in 11.2.3.1 to 11.2.3.2
221	11.2.3.1 Describe the expected problems.
222	
223	11.2.3.2 What criteria(s) will be used to assess pain, distress, or discomfort? Check all that
224	apply:
225	☐ Inactivity
226	Loss of appetite
227	\square Loss of weight \square 5% \square 10 % \square 15% \square 20% weight loss
228	Restlessness
229	lacksquare Abnormal resting postures, somnolence or hunched posture
230	Licking, biting, scratching, or shaking a particular area
231	☐ Failure to show normal patterns of inquisitiveness
232	☐ Failure to groom, causing and unkempt appearance
233	☐ Guarding (protecting the painful area)
234	Loss of mobility
235	lacktriangle Red stain around the eyes of rats
236	☐ Self-mutilation
237	☐ Labored breathing
238	☐ Tumor
239	☐ Unresponsiveness
240	Other (please list)
241	11.2.4 Literature search for alternative to procedure that cause pain & distress
242	11.2.4.1 Database(s) searched (Please specify the database name, e.g., PubMed,
243	ScienceDirect)):
244	

245	11.2.4.2 Date of literature search (must be within six months prior to submission
246	date) (<i>dd/m/yy</i>))
247	11.2.4.3 Range of years searched (To prevent the duplication of your proposed
248	experiment, the minimum period of search should be more than 5 years)
249	11.2.4.4 Key words used in search:
250	11.2.4.5 Results of search: Does the proposed research duplicate any previous work
251	□ No □ Yes
252	If YES, explain why it is scientifically necessary to duplicate previous
253	experiment.
254	
255	
256	11.3 Anesthesia
257	\square No \square Yes, please answer the following questions:
258	1) Preanesthetic preparation:
259	2) Anesthetic agent(s) used:
260	3) Dosage:
261	4) Volume:
262	5) Route of administration:
263	6) Frequency of anesthesia:
264	7) Length of anesthesia:
265	8) Who is responsible for monitoring anesthesia?
266	9) If an inhalation anesthetic is used, describe scavenging of the waste anesthetic gas.
267	
268	10) What criteria(s) will be used to assess level of anesthesia?
269	
270	Check all that apply:
271	\square Respiration rate \square Body temperature \square Heart rate
272	☐ ECG ☐ Toe pinch ☐ Tail pinch
273	☐ Corneal reflex ☐ Pedal reflex ☐ Muscular relaxation
274	Color of mucous membrane
275	☐ Other (pulse oximeter, respirometer) please list
276	11) How animals are kept warm?
277	11.4 Analgesics and/or tranquilizers:
278	\square No \square Yes, please specify
279	1) Type of analgesics used
280	Agent(s)
281	2) Dosage
282	3) Route of administration
283	4) Schedule

11.5 Describe post-anesthetic treatment or intervention:
12. Surgery: ☐ No —proceed to 13 ☐ Yes, answer all that apply in 12.1 to 12.7 12.1 Surgical procedure is: ☐ Non-survival ☐ Survival
Major
☐ One time ☐ Multiple
12.2 Location : (Give the location/room number for the proposed surgical procedure.)
12.3 Surgeon/qualification: (Indicate who will perform the surgery, and his/her
qualifications, training, or experience in the proposed procedure.)
12.4 Procedure: (Describe in detail the surgical procedure.)
12.5 Pre- and post-operative provision: (Detail the provision for both pre-and
post-operative care, including provisions for post-surgical observation.)
12.6 Describe long-term care of chronic survival procedure.
12.7 Multiple survival surgery procedures: (Multiple major operative procedures on the same
animal must be adequately justified for scientific reasons by the principal investigator in writing.)
12.7.1 Procedure:
12.7.2 Scientific justification:
12.7.3 Who will be the responsible for post-surgical care and treatment?
13. Blood or body fluid withdrawal/tissue collection/injections, tail clip, Gavage
(Describe in detail: method(s), needle size(s), volume(s) collected or administered, and
frequency of collection or injection.)

<u> </u>	, T	or injections,		ı		
Procedures	Anatomic	Needle	Biopsy	Volume	Volume	Frequency
	location	size/	size	collected	administered	
		catheter		(ml)	(ml)	
		size				
		and length				
Blood						
withdrawal						
Body Fluid						
withdrawal						
Tissue						

311

Procedures	Anatomic	Needle	Biopsy	Volume	Volume	Frequency
	location	size/	size	collected	administered	
		catheter		(ml)	(ml)	
		size				
		and length				
collection						
Injection						
Infusion						
Tail clip						
Gavage						
Other						
(specify)						

	(specijy)							
312	Total blood	volume	ml. in tota	ι	study day	s ormon	nths	
313	14. Use of non	-pharmaceı	utical grade co	ompound	ds			
314	14.1 Will ar	nimals be tr	eated with no	n-pharm	naceutical g	rade compound	ds?	
315	□ No —	-proceed to	15					
316	☐ Yes, a	answer all th	nat apply in 14	1.2 and 1	4.3			
317	14.2 Give ir	nformation (on name, sou	rce, form	nulation, co	ncentration, site	e and ro	oute
318	of administ	tration and	potential side	effects				
319								
320 321						non-pharmace		 grade
322	compound		. ,			The production		3
323								
324								
325	15. Restraint w	ith mechan	ical devices:					
326			Yes, ans	wer all th	nat apply in	15.1 and 15.2		
327	•				, , ,	f observation, c	ondition	ning
328			to assure com					3
329								
330								
331	15.2 Provid	e scientific	justification fo	or prolor	nged compl	ete restraint		
332								
333								
334	16. Project inv	olving food	and water de	eprivatio	n, or dietary	/ manipulation:		
335	16.1 Does t	:his protoco	l involve food	d or wate	er deprivatio	on or dietary ma	anipulat	ion?
336	□ No —	-proceed to	17					

					and sym _l
16.2 Provide det	ail of these	procedure	s in Table below		
Procedures	Amount restricted	Duration	Compound supplemented	Compound excluded	Freque
	or added				
Food deprivation					
Fluid deprivation					
Nutrient					
alteration					
expected	e criteria fo	r humane	endpoint in this p	protocol?	
18. Behavioral studion 18.1 Does this property No—pro	otocol invo		·		

367	19. Study endpoints
368	19.1 Describe the endpoint for the animals in this protocol. Indicate whether recovery,
369	euthanasia, or death is/are expected, and when the animal experimentation phase will be
370	stopped.
371	
372 373	19.2 Humane (early) endpoint is used (i.e., animals are humanely euthanized prior to
374	the expected day of termination)
375	□ No
376 377	☐ Yes, provide criteria for humane endpoint
378	
379 380	19.3 Death or moribund as an endpoint is used $\hfill \square$ No
381	Tes, answer all that apply in 19.3.1 to 19.3.2
382	19.3.1 Provide criteria that establish when this endpoint has been reached, and
383	describe how animals will be monitored and cared for
384	
385	19.3.2 List persons responsible for evaluating animal condition, record keeping, and
386	notifying PI and/or veterinarians to perform euthanasia
387	
388	20. Animal euthanasia and disposition
389	20.1 After completion of activity, the animals will be:
390	☐ Euthanized
391	☐ Returned to production/breeding unit/facility inventory
392	☐ Transferred to another research project:
393	Protocol No and name of principal
394	lacksquare Other, specify
395	20.2 Describe the two-step euthanasia method according to AVMA guidelines
396	This protocol uses:
397	Step 1 - Describe chemical method:
398	Immersion:
399	Pharmaceutical-grade clove oil at ml/L for minutes
400	☐ MS-222 at mg/L for minutes
401	Magnesium salts at mg/L for minutes
402	Ethanol at ml/L for minutes
403	2-phenoxyethanol at ml/L for minutes
404	Benzocaine at mg/L for minutes
405	☐ Lidocaine at mg/L for minutes

406	☐ Isoflura	ne at	mg/L for	minutes
407	☐ Sevoflu	rane at	mg/L for	minutes
408	☐ Quinalo	line sulfate at	mg/L for	minutes
409	\square Other, s	specify		
410	\square Injection:			
411	☐ Pentob	arbital at	mg/k	(षु
412	☐ Ketamii	ne at	mg/k	< द
413	☐ Ketamii	ne-medetomidine at	mg/k	< दु
414	\square Other, s	specify	_atmg/k	< दु
415	Route of a	dministration		
416	☐ Intram	uscular, 🗖 Intravenous,	☐ Intraperitoneal	, \square Intracoelomic,
417	☐ Intracar	diac		
418	Step 2 - Describe r	nechanical method:		
419	☐ Cervical tra	nsection		
420	☐ Chilling usi	ng: \square Ice, \square Cold water	for minutes	
421	☐ Cranial con	cussion		
422	☐ Decapitation	n		
423	☐ Exsanguina	tion		
424	☐ Maceration			
425	☐ Penetrating	captive bolt		
426	☐ Pithing			
427	☐ Other med	nanical method, specify		
428	☐ Use anothe	r method besides mechar	nical method, <i>describ</i> e	e and provide strong
429	scientific justif	cation		
430				
431				
432	20.3 State how death	will be verified before	disposal:	
433				
434	21. Necropsy/ Selected t	issue and sample collec	tion	
435	No		110	
436	☐ Yes, provide room	number, personnel with a	qualification	
437				
438				
439	22. Animal sample utilizat	ion and disposal:		
440	•	of animal samples, when	the primary research i	s completed, are anv
441	•	es used for other proposes	,	, , ,
442	□ No	1 1		
443	☐ Yes, please descri	be the specific parts and	d purpose(s), such as	s archival for future
	•		· · · · · · · · · · · · · · · · · · ·	

22.2 Animal tissue and carcasses disposal: Describe method used to dispose animal tiss and carcasses. 23. Occupational health and safety: 23.1 Select types of hazards associated with this protocol, also provide name, sour and amount to be used in each category Cancer cell lines Infectious agents provide the certificate of biosafety approval Hazardous chemicals (e.g., carcinogen, mutagen and teratogen) Recombination agents Recombination agents BBL-2 BBL-3 Other, specify None None 23.2 Specify biosafety level: BBL-1 BBL-2 BBL-3 23.3 Explain how the wastes associated with these hazards are decontaminated a disposed 23.4 Explain how the carcasses associated with these hazards and list any surveillar procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to line possible injury or illness		studies, inclusion in a teaching collection, donation to a museum, etc.
22.2 Animal tissue and carcasses disposal: Describe method used to dispose animal tis and carcasses. 23.1 Select types of hazards associated with this protocol, also provide name, sou and amount to be used in each category Cancer cell lines. Infectious agents provide the certificate of biosafety approval. Radiation equipment and radioactive elements. Recombination agents. Other, specify. None 23.2 Specify biosafety level: BSL-1 BSL-2 BSL-3 23.3 Explain how the wastes associated with these hazards are decontaminated a disposed. 23.4 Explain how the carcasses associated with these hazards are disposed. 23.5 Explain any safety precautions and protective measures (e.g., biosafety cabi and proper PPE) to protect personnel from those hazards and list any surveillar procedures in place to monitor any potential exposure.		
23.1 Select types of hazards associated with this protocol, also provide name, sociand amount to be used in each category Cancer cell lines Infectious agents provide the certificate of biosafety approval Hazardous chemicals (e.g., carcinogen, mutagen and teratogen) Radiation equipment and radioactive elements Recombination agents Other, specify None 23.2 Specify biosafety level: BSL-1 BSL-2 BSL-3 23.3 Explain how the wastes associated with these hazards are decontaminated a disposed 23.4 Explain how the carcasses associated with these hazards and list any surveilla procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to lipossible injury or illness		
23. Occupational health and safety: 23.1 Select types of hazards associated with this protocol, also provide name, sociand amount to be used in each category Cancer cell lines Infectious agents provide the certificate of biosafety approval Hazardous chemicals (e.g., carcinogen, mutagen and teratogen) Radiation equipment and radioactive elements Recombination agents Other, specify None 23.2 Specify biosafety level: BSL-1 BSL-2 BSL-3 23.3 Explain how the wastes associated with these hazards are decontaminated disposed Cancer cell lines Hazardous chemicals (e.g., carcinogen, mutagen and teratogen) Recombination agents Other, specify None SSL-1 BSL-2 BSL-3 SSL-3 SExplain how the wastes associated with these hazards are disposed Cancer cell lines Cancer cell lines Hazardous chemicals (e.g., carcinogen, mutagen and teratogen) Radiation equipment and radioactive elements Recombination agents Other, specify None 23.2 Specify biosafety level: BSL-1 BSL-2 BSL-3 23.3 Explain how the wastes associated with these hazards are disposed Cancer cell lines Cancer cell lines Hazardous chemicals (e.g., carcinogen, mutagen and teratogen) Recombination agents Recombination agents BSL-1 BSL-2 BSL-3 BSL-3 23.2 Specify biosafety level: BSL-1 BSL-2 BSL-3 BSL-3 23.3 Explain how the wastes associated with these hazards are disposed Cancer cell lines		and carcasses.
23.1 Select types of hazards associated with this protocol, also provide name, so and amount to be used in each category Cancer cell lines Infectious agents provide the certificate of biosafety approval Infectious agents Infectio		
and amount to be used in each category Cancer cell lines Infectious agents provide the certificate of biosafety approval Hazardous chemicals (e.g., carcinogen, mutagen and teratogen) Radiation equipment and radioactive elements Recombination agents Other, specify None 23.2 Specify biosafety level: BSL-1 BSL-2 BSL-3 23.3 Explain how the wastes associated with these hazards are decontaminated disposed 23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety caband proper PPE) to protect personnel from those hazards and list any surveilla procedures in place to monitor any potential exposure	23.	Occupational health and safety:
□ Cancer cell lines □ Infectious agents provide the certificate of biosafety approval □ Hazardous chemicals (e.g., carcinogen, mutagen and teratogen) □ Radiation equipment and radioactive elements □ Recombination agents □ Other, specify □ None 23.2 Specify biosafety level: □ BSL-1 □ BSL-2 □ BSL-3 23.3 Explain how the wastes associated with these hazards are decontaminated disposed 23.4 Explain how the carcasses associated with these hazards are disposed and proper PPE) to protect personnel from those hazards and list any surveillad procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to be possible injury or illness		23.1 Select types of hazards associated with this protocol, also provide name, so
☐ Infectious agents provide the certificate of biosafety approval ☐ Hazardous chemicals (e.g., carcinogen, mutagen and teratogen) ☐ Radiation equipment and radioactive elements ☐ Recombination agents ☐ Other, specify ☐ None 23.2 Specify biosafety level: ☐ BSL-1 ☐ BSL-2 ☐ BSL-3 23.3 Explain how the wastes associated with these hazards are decontaminated disposed 23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety cab and proper PPE) to protect personnel from those hazards and list any surveillad procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to be possible injury or illness		3 /
□ Hazardous chemicals (e.g., carcinogen, mutagen and teratogen) □ Radiation equipment and radioactive elements □ Recombination agents □ Other, specify □ None 23.2 Specify biosafety level: □ BSL-1 □ BSL-2 □ BSL-3 23.3 Explain how the wastes associated with these hazards are decontaminated disposed 23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety catand proper PPE) to protect personnel from those hazards and list any surveillate procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to be possible injury or illness		
□ Hazardous chemicals (e.g., carcinogen, mutagen and teratogen)		
Recombination agents Other, specify None 23.2 Specify biosafety level: BSL-1 BSL-2 BSL-3 23.3 Explain how the wastes associated with these hazards are decontaminated disposed 23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety calcand proper PPE) to protect personnel from those hazards and list any surveillar procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to be possible injury or illness		_
Other, specify None 23.2 Specify biosafety level: BSL-1 BSL-2 BSL-3 23.3 Explain how the wastes associated with these hazards are decontaminated disposed 23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety calcand proper PPE) to protect personnel from those hazards and list any surveillad procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to be possible injury or illness		☐ Radiation equipment and radioactive elements
23.2 Specify biosafety level: BSL-1 BSL-2 BSL-3 23.3 Explain how the wastes associated with these hazards are decontaminated disposed 23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety cab and proper PPE) to protect personnel from those hazards and list any surveillad procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to be possible injury or illness		Recombination agents
23.2 Specify biosafety level: BSL-1 BSL-2 BSL-3 23.3 Explain how the wastes associated with these hazards are decontaminated disposed 23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety catand proper PPE) to protect personnel from those hazards and list any surveilla procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to be possible injury or illness		Other, specify
23.4 Explain how the carcasses associated with these hazards are decontaminated disposed 23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety calcand proper PPE) to protect personnel from those hazards and list any surveillar procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to be possible injury or illness		None
23.5 Explain any safety precautions and protective measures (e.g., biosafety calcand proper PPE) to protect personnel from those hazards and list any surveilla procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to possible injury or illness		disposed
and proper PPE) to protect personnel from those hazards and list any surveilla procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to lipossible injury or illness		·
procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to l possible injury or illness		· · · · · · · · · · · · · · · · · · ·
23.6 In case of accident, provide immediate procedures and early treatment to l possible injury or illness		23.4 Explain how the carcasses associated with these hazards are disposed
possible injury or illness		23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety cab
		23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety calcand proper PPE) to protect personnel from those hazards and list any surveilla
		23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety calcand proper PPE) to protect personnel from those hazards and list any surveilla procedures in place to monitor any potential exposure
		23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety catand proper PPE) to protect personnel from those hazards and list any surveilla procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to lipossible injury or illness
	0.1	23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety calcand proper PPE) to protect personnel from those hazards and list any surveillar procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to be possible injury or illness
TIST OUT INDIVIDUALS VALIO VAID DE OITECTAV INVOLVED WITH THE ANTIHOUS ON THIS DYOIECT		23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety calcand proper PPE) to protect personnel from those hazards and list any surveilla procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to be possible injury or illness Qualification of teaching staff:
230 de marradas vino vine de <u>anocce,</u> move de vini de arminas on ens project.		23.4 Explain how the carcasses associated with these hazards are disposed 23.5 Explain any safety precautions and protective measures (e.g., biosafety calcand proper PPE) to protect personnel from those hazards and list any surveillar procedures in place to monitor any potential exposure 23.6 In case of accident, provide immediate procedures and early treatment to be possible injury or illness

 and laboratory assistants who will actually work with the animals. If personnel do not have experience, state how they will be trained:

Name	Responsibilities	Direct involvement with animal samples (%)	Relevant experience and qualification (e.g. How many years of experience working with animals or training related to the research)

As Principal investigator on this protocol, I verifies that the information herein is true and correct and that I am familiar with and will comply with standard of animal care and use established under the ethical guidelines and policies of Mahidol University, and Office of the National Research Council of Thailand (NRCT). Additionally, I acknowledge my responsibilities and provide assurances for the followings:

A. Animal use: The animals authorized for use in this protocol will be used only in the activities and in the manner described herein, unless a deviation is specifically approved by the MU-IACUC.

B. Duplication of effort: I have made a reasonable, good faith effort to ensure that this protocol is not an unnecessary duplication of previous experiments.

 C. Statistical assurance: I assure that I have consulted with qualified statistician to evaluate the statistical design or strategy of this proposal, and that the minimum number of animals needed for scientific validity are used.

D. Biohazard/safety: I have taken into consideration, and I have made the proper coordination's regarding all applicable rules and regulations concerning radiation protection, biosafety, recombinant issues, etc., in the preparation of this protocol.

E. Training: I verify that the personnel performing the animal procedures/manipulations described in this protocol are technically competent and have been properly trained to ensure that no unnecessary pain or distress will be caused as a result of the procedures/manipulations.

F. Responsibility: I acknowledge the inherent moral and administrative obligations associated with the performance of this animal use protocol, and I assure that all individuals associated with this project will demonstrate a concern for the health, comfort, welfare, and well-being of the research animals. Additionally, I pledge to conduct this study in the responsibility for implementing animal use alternatives where feasible, and conducting humane and lawful

research.

G. Scientific review: This proposed animal use protocol has received appropriate peer scientific review, and is consistent with good scientific research practice.

Protocol-Animal (Care	and	Use	Proto	ocol
			MU-	ACU	F0.5

513	Course coordinator		
514		()